| Literature DB >> 36128545 |
Sajal Kumar Halder1,2, Maria Mulla Mim3, Md Meharab Hassan Alif1, Jannatul Fardous Shathi1, Nuhu Alam4, Aparna Shil4, Mahbubul Kabir Himel4.
Abstract
Antimicrobial resistance is a major global health crisis, resulting in thousands of deaths each year. Antibiotics' effectiveness against microorganisms deteriorates over time as multidrug resistance (MDR) develops, which is exacerbated by irregular antibiotic use, poor disease management, and the evasive nature of bacteria. The World Health Organization has recognized multidrug resistance as a critical public health concern, and Acinetobacter baumannii has been at the center of attention due to its ability to develop multidrug resistance (MDR). It generally produces carbapenem-hydrolyzing oxacillinase, which has been identified as the primary source of beta-lactam resistance in MDR bacteria. Recently, point mutations in A. baumannii have been identified as a key factor of multidrug resistance, making them a prime concern for researchers. The goal of the current work was to establish a unique way of finding multidrug-resistant variants and identify the most damaging mutations in the existing databases. We characterized the deleterious variants of oxacillinases using several computational tools. Following a thorough analysis, Oxa-376 and Oxa-530 were found to be more damaging when compared with the wild-type Oxa-51. The mutants' 3D structures were then prepared and refined with RaptorX, GalaxyRefine, and SAVES servers. Our research incorporates seven antimicrobial agents to illustrate the resistance capability of the variants of oxacillinase by evaluating binding affinity in Autodock-vina and Schrodinger software. RMSD, RMSF, Radius of gyration analysis, the solvent-accessible surface area (SASA), hydrogen bonding analysis and MM-GBSA from Molecular Dynamics Simulation revealed the dynamic nature and stability of wild-type and Oxa-376 and Oxa-530 variants. Our findings will benefit researchers looking for the deleterious mutations of Acinetobacter baumannii and new therapeutics to combat those variants. However, further studies are necessary to evaluate the mechanism of hydrolyzing activity and antibiotic resistance of these variants. This journal is © The Royal Society of Chemistry.Entities:
Year: 2022 PMID: 36128545 PMCID: PMC9412156 DOI: 10.1039/d2ra02939a
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 4.036
Fig. 1Complete workflow of the study.
Details of selected point mutations of oxacillinase enzyme
| Variant name | GenBank ID | Point mutation |
|---|---|---|
| Oxa-51 | CAC83905.2 | Wild type |
| Oxa-132 | EU547447.1 | I263M |
| Oxa-219 | NG_049517.1 | L167V |
| Oxa-376 | NG_049667.1 | H93Y |
| Oxa-377 | NG_049668.1 | T51K |
| Oxa-411 | NG_049699.1 | A96T |
| Oxa-530 | KX599398.1 | T50S |
| Oxa-688 | NG_062310.1 | P194Q |
| Oxa-693 | NG_062315.1 | A216T |
| Oxa-702 | NG_062324.1 | L85I |
| Oxa-880 | KY126224.1 | D68N |
Functional and structural impact analysis by SHIFT, PolyPhen-2, PROVEAN, I-mutant, and PredyFlexy
| Variants | Mutation | SHIFT | PolyPhen-2 | PROVEAN | I-mutant (stability-RI) | PredyFlexy |
|---|---|---|---|---|---|---|
| OXA-132 | I263M | TOLERATED 0.07 | PROBABLY DAMAGING—0.998 (sensitivity: 0.27; specificity: 0.99) | Neutral = −1.163 | Decrease 9 | 1-INTERMEDIATE |
| Oxa-219 | L167V | TOLERATED 0.07 | PROBABLY DAMAGING—0.993 (sensitivity: 0.70; specificity: 0.97) | Deleterious = −2.881 | Decrease 8 | 1-INTERMEDIATE |
| Oxa-376 | H93Y | TOLERATED 0.23 | POSSIBLY DAMAGING—0.953 (sensitivity: 0.79; specificity: 0.95) | Neutral = −1.558 | Decrease 7 | 2-FLEXIBLE |
| Oxa-377 | T51K | TOLERATED 0.89 | BENIGN—0.014 (sensitivity: 0.96; specificity: 0.79) | Neutral = 0.221 | Decrease 7 | 2-FLEXIBLE |
| Oxa-411 | A96T | TOLERATED 0.27 | BENIGN—0.145 (sensitivity: 0.92; specificity: 0.86) | Neutral = −0.621 | Decrease 2 | 1-INTERMEDIATE |
| Oxa-530 | T50S | TOLERATED 0.11 | POSSIBLY DAMAGING—0.851 (sensitivity: 0.59; specificity: 0.75) | Neutral = −2.190 | Decrease 7 | 2-FLEXIBLE |
| Oxa-688 | P194Q | TOLERATED 0.41 | BENIGN—0.087 (sensitivity: 0.93; specificity: 0.85) | Neutral = 0.904 | Decrease 8 | 2-FLEXIBLE |
| Oxa-693 | A216T | AFFECT PROTEIN FUNCTION 0.03 | PROBABLY DAMAGING—0.998 (sensitivity: 0.27; specificity: 0.99) | Deleterious = −2.808 | Decrease 4 | 1-INTERMEDIATE |
| Oxa-702 | L85I | TOLERATED 0.59 | POSSIBLY DAMAGING—0.902 (sensitivity: 0.82; specificity: 0.94) | Neutral = −0.625 | Decrease 8 | 0-RIGID |
| Oxa-880 | D68N | TOLERATED 0.98 | BENIGN—0.015 (sensitivity: 0.96; specificity: 0.79) | Neutral = −0.907 | Decrease 5 | 2-FLEXIBLE |
Validation results of OXA-51, OXA-376, and OXA-530 variants using Verify3D, ERRAT, and PROCHECK service of SAVES server
| Models | Verify3D | Errat | PROCHECK | ||
|---|---|---|---|---|---|
| Residues with 3D-1D score > = 0.2 | Quality factor | Most favoured regions | Additional allowed regions | Most favoured region + additional allowed region | |
| OXA-51 | 80.66% | 95.4887 | 92.1% | 7.1% | 99.2% |
| OXA-376 | 97.19% | 95.279 | 90.3% | 9.7% | 100.0% |
| OXA-530 | 85.54% | 95.671 | 93.1% | 5.5% | 98.6% |
Binding affinity and nonbonded interaction between variant (Oxa-51) of oxacillinase enzyme and established antibiotics
| Drugs | Binding affinity (kcal mol−1) | Number of H bond | Interacting H bond with receptor (H-bond lowest distance) |
|---|---|---|---|
| Ampicillin | −6.5 | 8 | VAL143, VAL143, LEU142 (2.14178), SER218,TRP220 (2.0013), GLY144, LYS83, LYS83 |
| Cefaclor | −6.3 | 7 | LYS103 (1.85809), ASP134, ASP134, ARG137, ARG137, ARG137, ARG138 |
| Imipenem | −5.7 | 14 | SER218, SER257, SER257, ARG260, LYS125, LYS125 (1.86524), ALA216, MET124, LYS125, SER127, SER218, SER218, ALA126, GLU208 |
| Aztreonam | −6.7 | 3 | SER257 (2.37575), ARG260, ARG260 |
| DB04293 | −6.4 | 7 | LYS83, TRP220, ARG260, ARG260, LYS125 (1.90849), SER218 |
| Cefotaxime | −6.0 | 8 | LYS83, LYS83, SER218, SER257 (2.4812), ARG260, ARG260, SER257, LYS261 |
| Doripenem | −6.4 | 11 | SER218, ARG260, LYS125 (1.86524), ALA216, MET124, LYS125, SER127, SER218, SER218, ALA126, GLU208 |
Binding affinity and nonbonded interaction between variant (Oxa-376) of oxacillinase enzyme and established antibiotics
| Drugs | Binding affinity (kcal mol−1) | Number of H bond | Interacting H bond with receptor (H-bond lowest distance) |
|---|---|---|---|
| Ampicillin | −7.1 | 5 | LYS58, LYS58, ARG235 (1.96773), ARG235, PRO87 |
| Cefaclor | −6.9 | 4 | LYS58, ARG235 (1.96773), PRO87, ALA101 |
| Imipenem | −6.5 | 11 | ILE104 (1.94426), SER193, SER232, ARG235, ARG235, ALA191, LYS100, GLU182, SER193, SER102, SER102 |
| Aztreonam | −6.5 | 5 | SER232, SER232,ARG235 (2.03315), ARG235 |
| DB04293 | −7.6 | 4 | LYS58, SER193, SER102 (2.22038), SER102 |
| Cefotaxime | −7.1 | 8 | SER193 (2.01357), TRP195, SER232, ARG235, ARG235, LYS236, LYS236, GLU182 |
| Doripenem | −7.2 | 11 | SER102, TRP195, SER232, ARG235, ARG235, LYS236, ALA101 (1.92811), ALA101, GLU182, SER102, SER193 |
Binding affinity and nonbonded interaction between variant (Oxa-530) of oxacillinase enzyme and established antibiotics
| Drugs | Binding affinity (kcal mol−1) | Number of H bond | Interacting H bond with receptor (H-bond lowest distance) |
|---|---|---|---|
| Ampicillin | −7 | 5 | LYS58, SER193, SER232 (2.14911), ARG235, LYS236 |
| Cefaclor | −6.7 | 7 | LYS58, SER193, TRP195, ARG235 (1.93373), ARG235,SER193, LYS236 |
| Imipenem | −6 | 9 | LYS58, LYS58, TRP195, ARG235, ARG235 (1.9691), LYS100, GLU182, SER193 |
| Aztreonam | −6.5 | 13 | TRP195, SER232, SER232, ARG235, ARG235, ARG235, ARG235, SER102 (2.07985), LYS100, GLU182, SER193, SER193, SER193 |
| DB04293 | −6.1 | 4 | SER193, ARG235 (2.03406), ARG235, SER193 |
| Cefotaxime | −6.6 | 11 | LYS58, TRP197, SER232, ARG235, ARG235 (1.99628), ARG235, SER102, LYS100, GLU182, GLY194, TRP195 |
| Doripenem | −7.5 | 11 | LYS58, LYS58, SER193, TRP195, SER232, LYS236 (1.99728), LYS100, GLU182, GLU88, TRP195, SER102 |
Fig. 8(A) Schematic presentation of Root Mean Square Deviation (RMSD) plot of Oxa-51 (Green), Oxa-376 (Yellow) and Oxa-530 (Red). (B) Schematic presentation of Root Mean Square Fluctuation (RMSF) plot of Oxa-51 (Green), Oxa-376 (Yellow) and Oxa-530 (Red). (C) Schematic presentation of Radius of Gyration (Rg) plot of Oxa-51 (Green), Oxa-376 (Yellow) and Oxa-530 (Red). (D) Schematic presentation of Hydrogen bonds (H-bonds) plot of Oxa-51 (Green), Oxa-376 (Yellow) and Oxa-530 (Red). (E) Schematic presentation of plot for Solvent Accessible Surface Area (SASA) of Oxa-51 (Green), Oxa-376 (Yellow) and Oxa-530 (Red).
Fig. 9(A) Simulation plot of Root Mean Square Deviation (RMSD) showing Oxa-51 (Light Blue), Oxa-376 (Orange) and Oxa-530 (Grey), Oxa-51_Doripenam (Yellow), Oxa-51_Doripenam (Dark Blue), Oxa-51_Doripenam (Green). (B) Simulation plot of outcomes as Root Mean Square Fluctuation (RMSF) showing Oxa-51 (Light Blue), Oxa-376 (Orange) and Oxa-530 (Grey).
Fig. 10(A) Illustration of protein–ligand contact map of Oxa-51_Doripenem complex. (B) Illustration of protein–ligand contact map of Oxa-376_Doripenem complex. (C) Illustration of protein–ligand contact map of Oxa-530_Doripenem complex.
Fig. 11(A) Molecular dynamics simulation analysis of Oxa-51 protein structures of native and mutant models. (B) Schematic presentation of molecular dynamics simulation analysis of Oxa-376 protein structures of native and mutant models. (C) Molecular dynamics simulation analysis of Oxa-530 protein structures of native and mutant models.
Post dynamic MM-GBSA based binding free evaluation
| Name of complex | MM-GBSA (kcal mol−1) | |
|---|---|---|
| Δ | Δ | |
| Oxa-51_Doripenem | −33.50 ± 7.50 | −41.68 to −26.11 |
| Oxa-376_Doripenem | −41.22 ± 17.809 | −59.038 to −23.42 |
| Oxa-530_Doripenem | −38.775 ± 6.085 | −44.86 to −32.69 |
XP gscore and MM-GBSA scores between variant (Oxa-51) protein and established antibiotics
| Drugs | XP gscore (kcal mol−1) | MM-GBSA scores (kcal mol−1) |
|---|---|---|
| Aztreonam | −3.878 | −36.49 |
| Cefaclor | −3.833 | −26.13 |
| Doripenem | −3.8 | −38.53 |
| Ampicillin | −3.585 | −29.98 |
| DB04293 | −3.244 | −49.76 |
| Imipenem | −2.15 | −12.29 |
| Cefotaxime | −1.686 | −14.4 |
XP gscore and MM-GBSA scores between variant (Oxa-376) protein and established antibiotics
| Drug | XP gscore (kcal mol−1) | MM-GBSA scores (kcal mol−1) |
|---|---|---|
| Doripenem | −6.132 | −44.12 |
| Ampicillin | −5.467 | −30.47 |
| Imipenem | −5.021 | −37.65 |
| Cefotaxime | −4.756 | −36.9 |
| Cefaclor | −4.426 | −39.58 |
| Aztreonam | −4.258 | −34.9 |
| DB04293 | −4.098 | −37.32 |
XP gscore and MM-GBSA scores between variant (Oxa-530) protein and established antibiotics
| Drug | XP gscore (kcal mol−1) | MM-GBSA scores (kcal mol−1) |
|---|---|---|
| Cefotaxime | −5.666 | −41.48 |
| Imipenem | −5.555 | −40.06 |
| Cefaclor | −4.784 | −46.64 |
| Doripenem | −4.419 | −43.26 |
| Aztreonam | −4.259 | −44.02 |
| Ampicillin | −4.208 | −31.6 |
| DB04293 | −4.094 | −29.0 |